Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leadership changes at PhRMA

This article was originally published in Scrip

Executive Summary

The US innovator trade group PhRMAhas announced a number of leadership changes. Executive vice-president and chief operating officer Chris Singer has been named president of the international section. Diane Bieri, formerly senior vice-president, has been promoted to executive vice-president and remains general counsel. Chris Badgley will assume expanded duties as senior vice-president for government and public affairs; he previously was vice-president of state government affairs. International affairs vice-president Brian Toohey has been promoted to senior vice-president, and Jeff May has been named vice-president of international affairs. Federal affairs senior vice-president Alan Gilbert is leaving PhRMA in January to start his own consulting firm. He will be replaced by Bryant Hall, currently vice-president of federal affairs.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC030554

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel